Anixa Biosciences' (ANIX) Buy Rating Reiterated at HC Wainwright

Anixa Biosciences (NASDAQ:ANIX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright's target price would indicate a potential upside of 120.13% from the company's previous close.

Separately, EF Hutton Acquisition Co. I raised Anixa Biosciences to a "strong-buy" rating in a research note on Wednesday, August 7th.

Anixa Biosciences Stock Performance

NASDAQ:ANIX traded up $0.13 during trading hours on Tuesday, reaching $3.18. The company's stock had a trading volume of 48,390 shares, compared to its average volume of 109,238. The firm has a 50-day simple moving average of $3.26 and a 200-day simple moving average of $2.99. Anixa Biosciences has a 1 year low of $2.14 and a 1 year high of $5.13. The firm has a market capitalization of $102.33 million, a price-to-earnings ratio of -7.82 and a beta of 0.84.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its earnings results on Friday, September 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. Equities analysts anticipate that Anixa Biosciences will post -0.42 earnings per share for the current fiscal year.

Institutional Trading of Anixa Biosciences

Several large investors have recently bought and sold shares of the company. Virtu Financial LLC raised its position in shares of Anixa Biosciences by 47.2% in the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company's stock worth $50,000 after acquiring an additional 5,183 shares in the last quarter. Nations Financial Group Inc. IA ADV grew its stake in Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company's stock worth $50,000 after purchasing an additional 7,500 shares during the period. Concorde Asset Management LLC bought a new position in Anixa Biosciences in the second quarter worth $31,000. International Assets Investment Management LLC lifted its position in Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company's stock valued at $1,190,000 after buying an additional 23,800 shares during the period. Finally, Tyler Stone Wealth Management boosted its holdings in shares of Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company's stock valued at $132,000 after buying an additional 21,008 shares in the last quarter. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.